Photodynamic therapy. A review

Drugs and Aging

Volumn 15, Issue 1, 1999, Pages 49-68

  McCaughan Jr , James S ^a  

^a Laser Medical Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; BACTERIOCHLORIN; BENZOPORPHYRIN DERIVATIVE; HEMATOPORPHYRIN DERIVATIVE; HYPERICIN; LUTETIUM; MEROCYANINE; PHEOPHORBIDE; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE; PURPURIN; SINGLET OXYGEN; TALAPORFIN; TEMOPORFIN; UNCLASSIFIED DRUG;

BARRETT ESOPHAGUS; BREAST CANCER; BRONCHUS TUMOR; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; ESOPHAGUS TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IONIZING RADIATION; IRRADIATION; LASER; LIGHT; LIGHT ABSORPTION; ORAL DRUG ADMINISTRATION; OXIDATION; PAPILLOMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; REVIEW; SKIN CANCER; SKIN METASTASIS; TOPICAL DRUG ADMINISTRATION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DIHEMATOPORPHYRIN ETHER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SURVIVAL ANALYSIS;

EID: 0032783842     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199915010-00005     Document Type: Review

References (144)

1. 1. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998; 90 (12): 889-905
2. 2. Raab O. Biol Z 1900; 39: 524
3. 3. Tappeiner H, Jodlebauer A. Díe sensibilizierende wirkung fluorescierender substanzen. Leipzig: FCW Vogel, 1907
4. 4. Policard A. Etudes sur les aspects offerts par des tumeur experimentales examinee a la lumiere de woods. CR Soc Biol 1924; 91: 1423-8
5. 5. Blum, HF. Photodynamic action and diseases caused by light: American Chemical Society Monograph Series. New York: Rhineholt Publishing Corp., 1941
6. 6. Hausmann W. Biochem Z 1910; 30: 276
7. 7. Meyer-Betz F. Deut Arch Klin Med 1913; 112: S476
8. 8 Figge FHJ, Weiland GS, Manganiello LOJ. Cancer detection and therapy: affinity of neoplastic, embryonic, and traumatized tissues for porphyrins and metalloporphyrins. Proc Soc Exp Biol Med 1948; 68: 181-8
9. 9. Rassmussen-Taxdal DS, Ward GE, Figge FHJ. Fluorescence of human lymphatic and cancer tissues following high doses of intravenous hematoporphyrin. Cancer 1955; 1: 78-81
10. 10. Lipson RL, Baldes EJ. The photodynamic properties of a particular hematoporphyrin derivative. Arch Dermatatol 1960; 82: 509-16
11. 11. Lipson RL, Baldes EJ, Olsen AM. Hematoporphyrin derivative: a new aid of endoscopic detection of malignant disease. J Thorac Cardiovasc Surg 1961; 42: 623-9
12. 12. Lipson RL, Gray MJ, Baldes EJ. Hematoporphyrin derivative for detection and management of cancer. Proceedings of the IXth International Cancer Congress; 1966, 323
13. 13. Gregorie Jr HB, Horger EO, Ward JL, et al. Hematoporphyrin-derivative fluorescence in malignant neoplasms. Ann Surg 1968; 167: 820-8
14. 14. Diamond I, Granelli S, McDonagh AF. Photodynamic therapy of malignant tumors. Lancet 1972; 11: 1175-7
15. 15. Kelly JF, Snell ME. Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. J Urol 1976; 115: 150-1
16. 16. Weishaupt KR, Gomer CK, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in photo-inactivation of a murine tumor. Cancer Res 1976; 36: 2326-8
17. 17. Dougherty TJ, Kaufman JE, Goldfarb A, et al. Photoradiation therapy for the treatment of malignant tumors. Cancer Res 1978; 38: 2628-35
18. 18. Dougherty TJ, Thoma RE, Boyle DG, et al. Photoradiation therapy of malignant tumors: role of the laser. In: Pratesi R, Sacchi CA, editors. Lasers in photomedicine and photobiology. New York: Springer-Verlag, 1980: 67-75
19. 19. Hayata Y, Kato H, Konaka C, et al. Hematoporphyrin derivative and laser photoradiation in the treatment of lung cancer. Chest 1982; 81: 269-77
20. 20. Wile AG, Dahlman A, Burns RG, et al. Laser photoradiation therapy of cancer following hematoporphyrin sensitization. Lasers Surg Med 1982; 2 (2): 163-8
21. 21. McCaughan Jr JS, Guy JT, Hawley P, et al. Hematoporphyrin-derivative and photoradiation therapy of malignant tumors. Lasers Surg Med 1983; 3 (3): 199-209
22. 22. Hayata Y, Kato H. Laser and cancer therapy. Gan To Kagaku Ryoho 1983; 10 (6): 1387-94
23. 23. McCaughan Jr JS, Hicks W, Laufman L, et al. Palliation of esophageal malignancy with photoradiation therapy. Cancer 1984; 54: 2905-10
24. 24. Bruce Jr RA. Evaluation of hematoporphyrin photoradiation therapy to treat choroidal melanomas. Lasers Surg Med 1984; 4 (1): 59-64
25. 25. Dougherty TJ, Potter WR, Weishaupt KR. The structure of the active component of hematoporphyrin derivative. In: Dorion DR, Gomer CJ, editors. Porphyrin localization and treatment of tumors. New York: Alan R Liss Inc., 1984: 301-14
26. 26. McCaughan Jr JS, Ellison EC, Guy JT, et al. Photodynamic therapy for esophageal malignancy: a prospective twelve-year study. Ann Thorac Surg 1996; 62 (4): 1005-9
27. 27. McCaughan Jr JS, Williams TE. Photodynamic therapy for endobronchial malignant disease: a prospective fourteen-year study. J Thorac Cardiovasc Surg 1997; 114 (6): 940-6
28. 28. Agarwal R, Korman NJ, Mohan RR, et al. Apoptosis is an early event during phthalocyanine photodynamic therapy induced ablation of chemically induced squamous papillomas in mouse skin. Photochem Photobiol 1996; 63 (4): 547-52
29. 29. Zaidi SI, Oleinick NL, Zaim MT, et al. Apoptosis during photodynamic therapy-induced ablation of RIF-1 tumors in C3H mice: electron microscopic, histopathologic and biochemical evidence. Photochem Photobiol 1993; 58 (6): 771-6
30. 30. He XY, Sikes RA, Thomsen S, et al. Photodynamic therapy with photofrin II induces programmed cell death in carcinoma cell lines. Photochem Photobiol 1994; 59 (4): 468-73
31. 31. Laukka MA, Wang KK, Bonner JA. Apoptosis occurs in lymphoma cells but not in hepatoma cells following ionizing radiation and photodynamic therapy. Dig Dis Sci 1994; 39 (11): 2467-75
32. 32. Hotta S, Kashimura H, Hirai S, et al. Immediate changes in subcellular structures of transplanted tumours following photodynamic and laser hyperthermic therapy. Lasers Surg Med 1995; 16 (3): 262-71
33. 33. Luo Y, Chang CK, Kessel D. Rapid initiation of apoptosis by photodynamic therapy. Photochem Photobiol 1996; 63 (4): 528-34
34. 34. Kessel D, Luo Y, Deng Y, et al. The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem Photobiol 1997; 65 (3): 422-6
35. 35. Ratkay LG, Chowdhary RK, Iamaroon A, et al. Amelioration of antigen-induced arthritis in rabbits by induction of apoptosis of inflammatory cells with local application of transdermal photodynamic therapy. Arthritis Rheum 1998; 41 (3): 525-34
36. 36. Ketabchi A, MacRobert A, Speight PM, et al. Induction of apoptotic cell death by photodynamic therapy in human keratinocytes. Arch Oral Biol 1998; 43 (2); 143-9
37. 37. Fingar VH, Wieman TJ, Haydon PS. The effects of thrombocytopema on vessel stasis and macromolecular leakage after photodynamic therapy using photofrin. Photochem Photobiol 1997; 66 (4): 513-7
38. 38. Andrejevie-Blant S, Hadjur C, Ballini JP, et al. Photodynamic therapy of early squamous cell carcinoma with tetra(m-hydroxyphenyl)chlorin: optimal drug-light interval. Br J Cancer 1997; 76 (8): 1021-8
39. 39. van Geel IP, Oppelaar H, Rijken PF, et al. Vascular perfusion and hypoxic areas in RIF-1 tumours after photodynamic therapy. Br J Cancer 1996; 73 (3): 288-93
40. 40. Wang I, Andersson-Engels S, Nilsson GE, et al. Superficial blood flow following photodynamic therapy of malignant non-melanoma skin tumours measured by laser Doppler perfusion imaging. Br J Dermatol 1997; 136 (2): 184-9
41. 41. Korbelik M. Induction of tumour immunity by photodynamic therapy. J Clin Laser Med Surg 1996; 14 (5) 329-34
42. 42. Korbelik M, Naraparaju VR, Yamamoto N. Macrophage directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer 1997; 75 (2): 202-7
43. 43. Waterfield JD, Fairburst M, Waterfield EM, et al. Evaluation of the immunotoxicity of benzoporphyrin derivative (BPD-MA) in mice. Immunopharmacol Immunotoxicol 1997; 19 (1): 89-103
44. 44. Canti G, Lattuada D, Nicolin A, et al. Antitumour immunity induced by photodynamic therapy with aluminum disul fonated phthatocyanines und laser light. Anticancer Drugs 1994; 5 (4): 443-7
45. 45. Simkin GO, King DE, Levy JG, et al. Inhibition of contact hypersensitivity with different analogs of benzoporphyrin derivative. Immunopharmacology 1997; 37 (2-3): 221-30
46. 46. Pandey RK, Zheng G, Lee DA, et al. Comparative in vivo sensitizing efficacy of porphyrin and chlorin dimers joined with ester, ether, carbon-carbon or amide bonds. J Mol Recognit 1996; 9 (2): 118-22
47. 47. Bethel BH, McCaughan Jr JS, Pendley CE. Coproporphyrin and urobilinogen levels after intravenous injection of HpD [abstract]. Presented at the 4th Annual Meeting of the American Society for Laser Medicine and Surgery: 1984 Jun 4-6; Salt Lake City, 354
48. 48. Kessel D, Smith KM, Pandey RK, et al. Photosensitization with bacteriochlorins. Photochem Photobiol 1993; 58 (2): 200-3
49. 49. Hamblin MR, Newman EL. On the mechanism of the tumour-localising effect in photodynamic therapy. J Photochem Photobiol B 1994; 23 (1): 3-8
50. 50. Jori G, Reddi E. The role of lipoproteins in the delivery of tumour-targeting photosensitizers. Int J Biochem 1993; 25 (10): 1369-75
51. 51. Maziere JC, Morliere P, Biade S, et al. Antitumour photochemotherapy: biochemical bases, therapeutic uses and perspectives. C R Seances Soc Biol Fil 1992; 186 (1-2): 88-106
52. 2 of body surface? In: Dougherty TJ, editor. Optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy II. Vol. 1881. Proceedings of the International Society for Optical Engineering (SPIE): 1993 Jan 17-22: Los Angeles (CA). Bcllingham (WA): SPIE, 1993: 26-34
53. 53. McCaughan Jr JS, PDT of endobronchial tumours on the same day as injection of the photosensitizer DHE. Clin Laser Mon 1993; 57-8
54. 54. McCaughan Jr JS, PDT repeated without reinjection of photofrin (porfimer sodium). In: Dougherty TJ, editor. Optical methods for tumour treatment and detection: mechanisms and techniques in photodynamic therapy. Vol. 3247. Proceedings of the International Society for Optical Engineering (SPIE): 1998 Jan 27-29: San Jose (CA). Bellingham (WA): SPIE, 1998: 331-4
55. 55. McCaughan Jr JS, Hawley PC, Brown DG, et al. Effect of light dose on the photodynamic destruction of endobronchial tumours. Ann Thorac Surg 1992; 54 (4): 705-11
56. 56. Fingar VH, Potter WR, Henderson BW. Drug and light dose dependence of photodynamic therapy: a study of tumour cell clonogenecity and histologic changes. Photochem Photobiol 1987; 45: 643-50
57. 57. Georgakoudi I, Foster TH. Singlet oxygen-versus nonsinglet oxygen-mediated mechanisms of sensitizer photobleaching and their effects on photodynamic dosimetry. Photochem Photobiol 1998; 67 (6): 612-25
58. 58. McCaughan Jr JS, Guy JT, Hicks W, et al. Photodynamic therapy for cutaneous and subcutaneous malignant neoplasms. Arch Surg 1989; 124 (2): 211-6
59. 59. Waldow SM, Henderson BW, Dougherty TJ. Hyperthermic potentiation of photodynamic therapy employing photofrin I and II: comparison of results using three animal tumour models. Lasers Surg Med 1987; 7: 12-22
60. 60. Henderson BW, Bellnier DA. Tissue localization of photosensitizers and the mechanism of photodynamic tissue destruction [discussion 125-30]. Ciba Found Symp 1989; 146: 112-25
61. 61. Henderson BW, Bellnier DA, Greco WR, et al. An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy. Cancer Res 1997; 57 (18): 4000-7
62. 62. Akhlynma TV, Rosenkranz AA, Jans DA, et al. Insulin-mediated intracellular targeting enhances the photodynamic activity of chlorin c6. Cancer Res 1995; 55 (5): 1014-9
63. 63. Van Iperen HP, Schuitmaker HJ, Beijersbergen van Henegouwen GM. Non-specific systemic immune suppression induced by photodynamic treatment of lymph node cells with bacteriochlorin a. Photochem Photobiol B 1995; 28 (3): 197-202
64. 64. Yamazaki I, Sato Y, Sieber F. Role of cytoprolective mechanisms in the photochemical purging of autologous bone marrow grafts. Exp Hematol 1997; 25 (7): 629-37
65. 65. Muller S, Walt H, Dohler-Girdziunaite D, et al. Enhanced photodynamic effects using fractionated laser light. J Photochem Photobiol B 1998; 42(1): 67-70
66. 66. Veenhuizen RB, Ruevekamp MC, Oppelaar H, et al. Foscan-mediated photodynamic therapy for a peritoneal-cancer model: drug distribution and efficacy studies. Int J Cancer 1997; 73 (2): 230-5
67. 67. Luo Y, Kessel D. Initiation of apoptosis versus necrosis by photodynamic therapy with chloroaluminum phthalocyanine. Photochem Photobiol 1997; 66 (4): 479-83
68. 68. Minnock A, Vernon DI, Schofield J, et al. Photoinactivution of bacteria: use of a cationic water-soluble zinc phthatocyanine to photoinactivate both gram-negative and gram-positive bacteria. J Photochem Photobiol B 1996; 32 (3): 159-64
69. 69. Allemann E, Brasseur N, Kudrevich SV. Photodynamic activities and biodistribution of fluorinated zinc phthalocyanine derivatives in the murine EMT-6 tumour model. Int J Cancer 1997; 72 (2): 289-94
70. 70. Woodburn KW, Fan Q, Miles DR, Kessel D, et al. Localization and efficacy analysis of the phototherapeutic lutelium texaphyrin (PCI-0123) in the murine EMT6 sarcoma model. Photochem Photobiol 1997; 65 (3): 410-5
71. 71. Rifkin R, Reed B, Hetzel F, et al. Photodynamic therapy using SnET2 for basal cell nevus syndrome: a case report. Clin Ther 1997; 19 (4): 639-41
72. 72. Rocklin GB, Kelly HG, Anderson SC, et al. Photodynamic therapy of rat endometrium sensitized with tín ethyl etiopurpurin. J Am Assoc Gynecol Laparose 1996; 3 (4): 561-70
73. 73. Fisher AM, Danenberg K, Banerjee D, et al. Increased photosensitivity in HL60 cells expressing wild-type p53. Photochem Photobiol 1997; 66 (2): 265-70
74. 74. Kaplan MJ, Somers RG, Greenberg RH, et al. Photodynamic therapy in the management of metastatic cutaneous adenocarcinomas: case reports from phase 1/2 studies using tin ethyl etiopurpurin (SnET2). J Surg Oncol 1998; 67 (2): 121-5
75. 75. Hadjur C, Richard MJ, Parat MO, et al. Photodynamically induced cytotoxicity of hypericin dye on human fibroblast cell line MRC5. J Photochem Photobiol B 1995; 27 (2): 139-46
76. 76. Schmidt-Erfurth U, Miller J, Sickenberg M, et al. Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefes Arch Clin Exp Ophthalmol 1998; 236 (5): 365-74
77. 77. Husain D, Miller JW, Kenney AG, et al. Photodynamic therapy and digital angiography of experimental iris neovascularization using liposomal benzoporphyrin derivative. Ophthalmology 1997; 104 (8): 1242-50
78. 78. Trauner KB, Gandour Edwards R, Bamberg M, et al. Photodynamic synovectomy using benzoporphyrin derivative in an antigen-induced arthritis model for rheumatoid arthritis. Photochem Photobiol 1998; 67 (1) 133-9
79. 74. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990; 6 (1-2): 143-8
80. 80. Loh CS, MacRobert AJ, Bedwell J, et al. Oral versus intravenous administration of 5-aminolacvulinic acid for photodynamic therapy. Br J Cancer 1993; 68 (1): 41-51
81. 81. Tope WD, Ross EV, Kollias N, et al. Protoporphyrin IX fluorescence induced in basal cell carcinoma by oral delta-aminolevulinic acid. Photochem Photobiol 1998; 67 (2): 249-55
82. 82. Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998; 114 (3): 448-55
83. 83. Regula J, MacRobert AJ, Gorchein A, et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX: a pilot study. Gut 1995; 36 (1): 67-75
84. 84. Peng Q, Warloe T, Moan J, et al. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol 1995; 62 (5): 906-13
85. 85. Calzavara-Pinton PG. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach in the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B 1995; 29 (1): 53-7
86. 86. Wennberg AM, Lindholm LE, Alpsten M, et al. Treatment of superficial basal cell carcinomas using topically applied delta-aminolaevulinic acid and a filtered xenon lamp. Arch Dermatol Res 1996; 288 (10): 561-4
87. 87. Fijan S, Honigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. Br J Dermatol 1995; 133 (2): 282-8
88. 88. Fink-Puches R, Hofer A, Smolte J, et al. Primary clinical response and long-term follow-up of solar keratoses treated with topically applied 5-aminolevulinic acid and irradiation by different wave bands of light. J Photochem Photobiol B 1997; 41 (1-2): 145-51
89. 89. Fritsch C, Stege H, Saalmann G, et al. Green light is effective and less painful than red light in photodynamic therapy of facial solar keratoses. Photodermatol Photoimmunol Photomed 1997; 13 (5-6): 181-5
90. 90. Klock J, Akkermans W, Beijersbergen van Henegouwen GM. Derivatives of 5-aminolevulinic acid for photodynamic therapy: enzymatic conversion into protoporphyrin. Photochem Photobiol 1998; 67 (1): 150-4
91. 91. Cairnduff F, Stringer MR, Hudson EJ, et al. Superficial photodynamic therapy with topical 5-aminolacvulinic acid for superficial primary and secondary skin cancer. Br J Cancer 1994; 69 (3): 605-8
92. 92. Waidelich R, Hofstetter A, Stepp H, et al. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of upper tract urothelial tumours. J Urol 1998; 159 (2): 401-4
93. 93. Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy: clinical research and future challenges. Cancer 1997, 79 (12): 2282-308
94. 94. McCaughan Jr JS, Ellison EC, Guy JT, et al. Photodynamic therapy for esophageal malignancy: a prospective 12 year study. Ann Thorac Surg 1996; 62: 1005-10
95. 95. Overholt BF, Panjehpour M. Photodynamic therapy for Harrett's esophagus: clinical update. Am J Gastroenterol 1996; 41 (9): 1719-23
96. 96. Spinelli P, Mincini A, Dal Fante M. Endoscopic treatment of gastrointestinal tumours: indications and results of laser photocoagulation and photodynamic therapy. Semin Surg Oncol 1995; 11 (4): 307-18
97. 97. Sibille A, Lambert R, Souquet J, et al. Long-term survival after photodynamic therapy for esophageal carcinoma. Gastroenterology 1995; (108): 337-44
98. 98. McCaughan JS Jr. Photodynamic therapy versus Nd-Yap laser treatment of endobronchial or esophageal malignancies. In: Spinelli P. Dal Fante M, Marchesini R, editors. Photodynamic therapy and biomedical lasers. Elsevier Science Publishers: New York, 1992: 23-36
99. 99. Lightdale CJ, Heier SK, Marcon NE, et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd: YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc 1995; 42 (6): 507-12
100. 100. Hesketh PJ, Clapp RW, Doos WG, S, et al. The increasing frequency of adenocarcinoma of the esophagus. Cancer 1989; 64: 526-30
101. 101. Blot WJ, Devesa SS, Knelter RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-9
102. 102. Birgisson S, Rice TW, Kirk A, et al. The lack of association of between adenocarcinoma of the esophagus and gastric surgery: a retrospective study. Am J Gastroenterol 1997; 92: 216-21
103. 103. Kirby TJ, Rice TW. The epidemiology of esophageal carcinoma, in chest surgery clinics of North America. In: Rice TW, Kirby TJ, editors. Esophageal carcinoma. Vol. 4 (2). Philadelphia: WB Saunders, 1994: 217-25
104. 104. Hansen S, Wilg JN, Giereksky KE, et al. Esophageal and gastric carcinoma in Norway 1958-1992: incidence time trend variability according to morphological subtypes and organ subsites. Int J Cancer 1997; 71: 340-4
105. 105. Phillips RW, Wong RKH. Barrett's esophagus: natural history, incidence, etiology and complications. Gastroenterol Clin North Am 1991; 20: 791-817
106. 106. Reid BJ. Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 1991; 20: 817-34
107. 107. Clark GW, Smyrk TC, Burdiles P, et al. Is Barrett's metaplasia the source of adenocarcinoma of the cardia? Arch Surg 1994; 129: 609-14
108. 108. Ollyo JB, Monnier P, Fontolliel C, et al. The natural history, prevalence and incidence of reflux oesophagitis. Gullet 1993; Suppl. 3: 3-10
109. 109. Orlando RC. Reflux esophagitis. In: Yamada T, Alpers DH, Owang C, et al., editors. Textbook of gastroenterology. 2nd ed. Philadelphia: JB Lippincott, 1995: 1214-42
110. 110. Criman DK, Riddell RH. The distinction between adenocarcinoma of the cardia and Barrett's cancer. In: Wastell C, Nyhus LM Donahue PE, editors. Surgery of the esophagus, stomach and small intestine, Boston: Little, Brown and Company, 1995: 236-53
111. 111. Ott DJ, Wu WC. Gelfand DW. Reflux esophagitis revisited: prospective analysis of radiological accuracy. Gatrointest Radiol 1981; 6: 1
112. 112. Kerlin P, d'Mellow G, van Deth A. Barrett's esophagus: clinical, endoscopic, and histologic-spectrum in fifty patients. Aust N Z J. Med 1986; 16: 198-205
113. 113. Biddlestone LR, Barham CP, Wilkinson SP, et al. The histopathology of treated Barrett's esophagus: squamous reepithelialization after acid suppression and laser and photodynamic therapy. Am J Surg Pathol 1998; 22 (2): 239-45
114. 114. McCaughan Jr JS, Williams T. Photodynamic therapy for endobronchial malignancy: a prospective 14 year study. J Thorac Cardiovasc Surg 1997; 114 (6): 940-6
115. 115. McCaughan Jr JS, Barabash R, Hawley P. Stage III andobronchial squamous cell cancer: survival after Nd:YAG laser combined with photodynamic therapy vs Nd:YAG laser or photodynamic therapy alone. In: Dougherty TJ, editor. Optical methods for tumour treatment and detection: mechanisms and techniques in photodynamic therapy. Vol. 1426. Proceedings of the International Society for Optical Engineering (SPIE); 1991 Jan 20-25: Los Angeles (CA). Bellingham (WA): SPIE, 1991: 279-87
116. 116. Kato H, Okunaka T, Shimatani H. Photodynamic therapy for early stage bronchogenic carcinoma. J Clin Laser Med Surg 1996; 14 (5): 235-8
117. 117. Cortese DA, Edell HS, Kinsey JH. Photodynamic therapy for early stage squamous cell carcinoma of the lung. Mayo Clin Proc 1997; 72 (7): 595-602
118. 118. McCaughan Jr JS, Williams Jr T, Hawley P, et al. Endobronchial photodynamic therapy for hemoptysis. In: Dougherty TJ, editor. Optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy. Vol. 2133. Proceedings of the International Society for Optical Engineering (SPIE): 1994 Jan 23-29: Los Angeles (CA). Bellingham (WA): SPIE, 1994: 2-9
119. 119. McCaughan Jr JS, Hawley PC, LaRosa JC, et al. Photodynamic therapy to control life-threatening hemorrhage from hereditary hemorrhagic telangiectasia. Lasers Surg Med 1996; 19 (4): 492-4
120. 120. Shikowitz MJ, Abramson AL, Freeman K, et al. Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope 1998; 108 (7): 962-7
121. 121. McCaughan Jr JS. Photodynamic therapy of skin and esophageal cancers. Cancer Invest 1990; (8): 407-16
122. 122. Khan SA, Dougherty TJ, Mang TS. An evaluation of photodynamic therapy in the management of cutaneous metastases of breast cancer. Eur J Cancer 1993; 29A (12): 1686-90
123. 123. McCaughan Jr JS, Mertens BF, Cho C, et al. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts: a case report. Arch Surg 1991; 126(1): 111-3
124. 124. Schuller DE, McCaughan Jr JS, Rock RP. Photodynamic therapy in head and neck cancer. Arch Otolaryngol 1985; 111 (6): 351-5
125. 125. Biel MA. Photodynamic therapy of head and neck cancers. Semin Surg Oncol 1995; 11 (5): 355-9
126. 126. Schweitzer VG, Visscher D. Photodynamic therapy for treatment of AIDS-related oral Kaposi's sarcoma. Otolaryngol Head Neck Surg 1990; 102 (6): 639-49
127. 127. Hebeda KM, Huizing MT, Brouwer PA, et al. Photodynamic therapy in AIDS-related cutaneous Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 (1): 61-70
128. 128. Nseyo UO, Shumaker B, Klein EA, et al. Photodynamic therapy using poefimer sodium as an alternative to cystectomy in patients with retractory transitional cell carcinoma in situ of the bladder. J Urol 1998; 160 (1): 39-44
129. 129. Lee LK, Whitehurst C, Pantelides ML, et al. In situ comparison of 665 nm and 633 nm wavelength light penetration in the human prostate gland. Photochem Photobiol 1995; 62 (5): 882-6
130. 130. Chang SC, Buonaccorsi GA, MacRobert AJ, et al. Interstitial photodynamic therapy in the canine prostate with disultonated aluminum phthalocyanine and 5-aminolevulinic acid-induced protoporphyrin IX. Prostate 1997; 32 (2): 89-98
131. 131. Muller PJ, Wilson BC. Photodynamic therapy for recurrent supratentorial gliomas. Semin Surg Oncol 1995; 11 (5): 346-54
132. 132. Kaye AH, Hill JS. Photodynamic therapy of brain tumours. Ann Acad Med Singapore 1993; 22 (3 Suppl.): 470-81
133. 133. Ward BG, Forbes IJ, Cowled PA, et al. The treatment of vaginal recurrences of gynecologic malignancy with phototherapy following hematoporphyrin derivative pre-treatment. Am J Obstet Gynecol 1982; 142: 356-7
134. 134. Soma H, Nutabara S. Cancer of the female genitalia. In: Hayata Y, Dougherty TJ, editors. Lasers and hematoporphyrin derivative in cancer. New York: Igaku-Shoin, 1983: 97-109
135. 135. Monk BJ, Brewer C, Van Nostrand K, et al. Photodynamic therapy using topically applied dihematoporphyrin ether in the treatment of cervical intraepithelial neoplasia. Gynecol Oncol 1997; 64 (1): 70-5
136. 136. McCaughan Jr JS, Schellhas HE, Lomano J, et al. Photodynamic therapy of gynecologic neoplasms after presensitization with hematoporphyrin derivative. Lasers Surg Med 1985; 5: 491-8
137. 137. Pass HI. Temeck BK. Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleurul mesothelioma. Ann Surg Oncol 1997; 4 (8): 628-33
138. 138. Takita H, Dougherty TJ. Intracavitary photodynamic therapy for malignant pleural mesothelioma. Semin Surg Oncol 1995; 11 (5): 368-71
139. 139. Baas P, Murrer L, Zoetmulder FA, et al. Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br J Cancer 1997; 76 (6): 819-26
140. 140. Chang CJ, Lee YH, Yang JY, et al. Pilot in vitro toxicity study of 5-ALA and photofrin in microvascular endothelial cell cultures. J Clin Laser Med Surg 1997; 15 (2): 83-7
141. 141. Gonschior P, Vogel-Wiens C, Goetz AE, et al. Endovascular catheter-delivered photodynamic therapy in an experimental response to injury model. Basic Res Cardiol 1997; 92 (5): 310-9
142. 142. Litvack F, Grundfest WS, Forrester JS, et al. Effects of hematoporphyrin derivative and photodynamic therapy on atherosclerotic rabbits. Am J Cardiol 1985; 56 (10); 667-71
143. 143. Jamieson CH, McDonald WN, Levy JG. Preferential uptake of benzoporphyrin derivative by leukemic versus normal cells. Leuk Res 1990; 14 (3): 209-19
144. 144. Gluck S, Chadderton A, Ho AD. The selective uptake of benzoporphyrin derivative mono-acid ring A results in differential cell kill of multiple myeloma cells in vitro. Photochem Photobiol 1996; 63 (6): 846-53